Compare PPCB & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPCB | NAII |
|---|---|---|
| Founded | 2007 | 1980 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 21.2M |
| IPO Year | N/A | 1987 |
| Metric | PPCB | NAII |
|---|---|---|
| Price | $0.47 | $4.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 68.1K | 16.1K |
| Earning Date | 02-15-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $134,440,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 19.00 |
| 52 Week Low | $0.50 | $2.57 |
| 52 Week High | $145.46 | $4.31 |
| Indicator | PPCB | NAII |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 80.20 |
| Support Level | N/A | $3.14 |
| Resistance Level | N/A | $3.55 |
| Average True Range (ATR) | 0.00 | 0.18 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 0.00 | 87.66 |
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.